Status:
COMPLETED
Predictors of the Response to Adalimumab in Rheumatoid Arthritis
Lead Sponsor:
University Hospital, Rouen
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease which is characterized by joint inflammation (clinical involvement), by osteo-cartilaginous lesions (structural damage) and ...
Eligibility Criteria
Inclusion
- ACR classification criteria of RA
- DAS 28 \> 5.1
- inadequately controlled by at least one DMARD
- biologics naïve
Exclusion
- exclusion criteria of adalimumab and methotrexate (regulation authorities)
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00234234
Start Date
January 1 2006
End Date
December 1 2008
Last Update
February 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MARCELLI
Caen, Basse Normandie, France, 14